contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


prostalund-has-submitted-an-application-for-ce-marking-of-its-new-treatment-platform

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

ProstaLund

ProstaLund announces today that the company has submitted the technical documentation for its new platform to its notified body, TÜV SÜD. This is the final phase in the CE marking process of...

<div class="mfn-preamble"><p><strong>ProstaLund announces today that the company has submitted the technical documentation for its new platform to its notified body, TÜV SÜD. This is the final phase in the CE marking process of ProstaLund's new treatment platform CoreTherm® Eagle.</strong></p></div><div class="mfn-body"><p>A notified body is an independent third party appointed by a competent authority to verify that the product is safe from a clinical, safety and user perspective. The CE mark verifies a company's clinical claims that a product meets the essential requirements of the Medical Devices Regulations (MDR), and it is a legal requirement for a product to be sold on the market within the EU. TÜV's evaluation is expected by the company to be completed during the first quarter of 2023. After obtaining the CE mark, the product will be available for sale in Europe.</p><p>CoreTherm® Eagle is an updated and modernized platform for performing ProstaLund's treatment of benign prostatic enlargement, CoreTherm® Concept. CoreTherm® Eagle combines the proven and well-documented technology from previous CoreTherm® platforms with a newly developed, simplified, and modern user interface and software updates in order to provide improved method support for treating physicians and increased safety for treated patients.</p><p>“The development work of CoreTherm® Eagle began long before I arrived at ProstaLund and after a re-start in the spring of 2020, it feels incredibly nice that we have now reached this milestone. This is a very important piece of the puzzle to be able to take CoreTherm® towards a wider use and we will now have full focus on planning and preparing for the launch of CoreTherm® Eagle.” comments CEO Johan Wennerholm</p></div><div class="mfn-footer"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p>Johan&nbsp;Wennerholm,&nbsp; CEO<br>Tel. +46 (0) 730 429997<br>Email: johan.wennerholm@prostalund.com</p></div><div class="mfn-footer mfn-about"><p><strong class="mfn-heading-1">About ProstaLund</strong></p><hr><p>ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company’s lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.</p><p><strong>Certified Adviser</strong>:<br>Västra Hamnen Corporate Finance AB<br>Phone: +46 40 200 250<br>E-mail: <a rel="nofollow noopener" href="mailto:ca@vhcorp.se">ca@vhcorp.se</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="nofollow noopener" href="https://storage.mfn.se/9eed44ee-02ff-4a83-818d-78daca1d48cb/prostalund-has-submitted-an-application-for-ce-marking-of-its-new-treatment-platform.pdf" class="mfn-generated mfn-primary">ProstaLund has submitted an application for CE marking of its new treatment platform</a></p></div>

ProstaLund has submitted an application for CE marking of its new treatment platform